For laboratory research use only. Not for human or veterinary use.
Cagrisema is a research combination studied for interaction between amylin-related pathways and GLP-1 receptor signaling.
| Total Content | Volume | Concentration | 0.1 mL | 0.2 mL | 0.4 mL | 1.0 mL |
|---|---|---|---|---|---|---|
| 10mg | 1mL | 10mg/mL | 1mg | 2mg | 4mg | 10mg |
Quantified to verify concentration within accepted labeled specification.
Assessed for peptide purity and absence of significant impurities by analytical methods.
Confirmed by analytical testing to match reference peptide characteristics.
Batch records and test data maintained for traceability and transparency.
Cagrisema is a combination research formulation commonly studied for amylin-related and GLP-1 receptor pathway activity.
Semaglutide is studied as a GLP-1 receptor agonist. Cagrisema is studied as a combination involving GLP-1 and amylin-related pathways.
It is commonly studied in metabolic signaling, appetite-related pathways, satiety signaling, and glucose-response research models.
This product is supplied strictly for laboratory research use only and is not intended for human or veterinary use.